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A B S T R A C T
The aim of the study was to investigate the association between methylenetetrahydrofolate (MTHFR) genotypes and
levels of homocysteine (Hcy), folate, vitamin B12 and lipids as well as the association between apolipoprotein E (apo E)
genotypes and levels of lipids in a Croatian healthy control group and a group of patients with >70% carotid stenosis
(CS). The study included 98 Croats, 38 patients with >70% carotid stenosis and 60 age- and sex-matched controls. The
MTHFR and apo E genotypes were determined by polymerase chain reaction-restriction fragment length polymorphism
(PCR-RFLP), Hcy by enzyme immunoassay, vitamins by immunochemiluminiscence, and lipids by spectrophotometric
method. There was no difference between control subjects and CS patients in the distribution of C677T MTHFR geno-
types (p=0.786) and alleles (p=0.904), however, differences in the frequencies of apo E genotypes (p=0.012) and alleles
(p=0.029) were statistically significant. The odds ratio for apo E 3/4 genotype was 3.93 (95% CI 1.23–12.61). Hyperho-
mocysteinemia (15 mol/L) was found in 11% of CS patients and 5% of control subjects. Total cholesterol, triglycerides,
vitamin B12 and folate were statistically different in »all MTHFR genotypes« (p0.001, p0.01, p=0.044 and p=0.036,
respectively), and in TC/TT (p0.001, p=0.003, p=0.030 and p=0.032, respectively) groups. The levels of total choles-
terol, LDL cholesterol and triglycerides in the apo E 3/3, and total cholesterol in the apo E 3/4 group yielded statistical
difference. An association was found of apo E 3/4 genotype but not of MTHFR genotypes with the risk of CS. MTHFR
and apo E affect blood lipid levels, which was statistically confirmed. An association was also recorded between hyper-
homocysteinemia and patients with CS. Vitamin status in CS showed a statistically verified association with TC/TT
MTHFR genotype. In the group of patients with TC/TT MTHFR genotype, lower vitamin B12 and higher folate values
were recorded. The results of multiple logistic analysis showed that there was no statistical significance of Hcy levels
(OR 2.403, p=0.334) or conventional vascular risk factors such as smoking habit (OR 0.505, p=0.149), age (OR 1.048,
p=0.087) or sex (OR 2.037, p=0.112) in predicting CS.
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Introduction
Extracranial atherosclerotic carotid disease is the
leading cause of stroke and transient ischemic attacks
(TIA) in Western populations1. In addition to the estab-
lished risk factors for atherosclerosis (diabetes, tobacco
use, decreased high-density lipoprotein level, hyperlipi-
demia, hypertension, positive family history, etc.), epide-
miologic data indicate that elevated homocysteine (Hcy)
concentrations are associated with an increased risk of
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cardiovascular disease, including coronary artery dis-
ease, cerebrovascular disease and peripheral arterial oc-
clusive disease1,2.
Hcy is a putatively atherothrombotic sulfur amino
acid produced during methionine metabolism. It is cata-
bolized to cystathionine and cysteine by cystathionine
$-synthase. Significant amounts of methionine may be
regenerated by the remethylation pathway, a reaction
catalyzed by methionine synthase. Vitamin B12 is a co-
factor and methyltetrahydrofolate a substrate in this re-
action. Methyltetrahydrofolate, the predominant circu-
lating form of folate found in the blood, is formed in a
reaction catalyzed by 5,10-methylene tetrahydrofolate
reductase (MTHFR). This enzyme has a strong indirect
influence on Hcy remethylation3. The main determi-
nants of mild hyperhomocysteinemia are folate and B12
intake, impaired renal function, and genetic factors3.
A common missense mutation, C677T, has been iden-
tified in the MTHFR gene where alanine is substituted
by valine, which results in a thermolabile variant of the
reductase4,5. The data have shown that the frequency of
the mutation varies among different populations6,7, and
the association of MTHFR genotype and carotid artery
atherosclerosis has been controversial7–10.
High levels of total and low density lipoprotein (LDL)
cholesterol and low levels of high density lipoprotein
(HDL) cholesterol are known to predispose to the devel-
opment of atherosclerosis11,12. Also, lipid metabolism in
humans is strongly affected by polymorphisms of a num-
ber of genes11. The apolipoprotein E (apo E) gene, which
also belongs to this group, is located on chromosome 19
and has three common allelic variants known as apo E*2
( 2), apo E*3 ( 3) and apo E*4 ( 4)12. Studies of apo E al-
lele distributions in different ethnic groups have shown
similar patterns for most Caucasian populations. The  3
allele is most common, with frequencies between 0.70
and 0.85,  4 is less frequent, 0.10–0.20, and  2 is the rar-
est one with a frequency of 0.05–0.1013. Also, it is already
known that the prevalence of apo E allele differs among
populations14. Additionally, studies on apo E and carotid
atherosclerosis have yielded inconsistent results10,15–20.
As this association has not yet been fully clarified, addi-
tional research is needed for definite conclusions21.
The aim of our study was to investigate the associa-
tion between MTHFR genotypes and levels of Hcy, folate,
vitamin B12 and lipids as well as the association between
apo E genotypes and levels of lipids in a Croatian healthy




In this study, C677T MTHFR and apo E genotypes as
well as blood lipid, homocysteine and vitamin (vitamin
B12 and folate) levels were determined in 98 subjects,
residents of Zagreb. Patients (38 patients; 9 female and
29 male, mean age 629 years) with a severe carotid ste-
nosis (>70%) according to the ECST criteria were inclu-
ded22. All patients had a clinical diagnosis of atheroscle-
rosis based on ultrasonography color Doppler imaging
findings. The control group included 60 sex- and age-
matched healthy volunteers. EDTA-blood was collected
by venipuncture after an overnight fast and important
exclusion criteria was using of multivitamins. Patient
group was under medication treatment (aspirin, anti-
hypertensive or oral antidiabetics) which was adminis-
tered after blood drawing. An informed consent was re-
ceived from each subject prior to analysis. The study was
approved by the Ethics Committee of the University
Hospital »Sestre milosrdnice«, Zagreb.
C677T MTHFR and apo E genotyping
The C677T MTHFR gene mutation and apo E geno-
types were detected by a DNA-based method consisting
of DNA isolation and polymerase chain reaction-restric-
tion fragment length polymorphism (PCR-RFLP)4,7,23.
Leukocyte DNA was isolated by the phenol/chloroform/
isoamyl alcohol extraction and ethanol precipitation me-
thod24,25.
The C677T substitution in the MTHFR was identified
as previously described4,7. The apo E genotypes were
identified by a slightly modified method described by
Dallinga-Thie et al.24. Briefly, target DNA (0.3 (g) was
amplified by PCR using PCR Core Kit (Roche Diagnos-
tics, Mannheim, Germany) and two specific primers
(MWG Biotech, Ebersberg, Germany) in a DNA thermal
cycler (ProGene thermal cycler, Techne, Duxford, Cam-
bridge, UK). The sequence of primers used for MTHFR
gene amplification was: 5)- tgaaggagaaggtgtctgcggga-3)
and 5)-aggacggtgcggtgagagtg-3’; and the sequence of pri-
mers for apo E gene amplification was: P1:5)- agaatt-
cgccccggcctggtacac-3) and P2: 5)-taagcttggcacggctgtccaagga-
3). The fragments were amplified separately, in reaction
volume of 50 (L using 0.25 (M primers, 200 (M dNTP,
1X PCR buffer with 1.5 mM MgCl2 and 1 U Taq polymer-
ase. Formamide (1 (L/50 (L) was added in the reaction
mixture of apo E gene amplification as a procedure modi-
fication resulting in a higher quantity of specific PCR
product with a very sharp and bright band on the gel
photography.
Each reaction mixture was subjected to 30 cycles of 30
s at 95 °C, 30 s at 60 °C and 60 s at 72 °C, initial denatur-
ation for 5 min at 95 °C, final extension for 5 min at 72 °C.
PCR products (198 bp of MTHFR gene, and 244 bp of apo
E gene) were checked electrophoretically in a Clearose
BG-ET gel (Elchrom Scientific AG, Basel, Switzerland)
using SEA 2000 apparatus (Guest Elchrom Scientific
AG, Basel, Switzerland) in 30 mM Tris-acetic-EDTA
(TAE) buffer. Negative quality controls generated by in-
clusion of all reagents except for DNA and positive qual-
ity control containing a known genotype were included
in every run. Positive quality control containing a known
apo E genotype was obtained by the courtesy of Dallin-
ga-Thie GM, Department of Medicine and Endocrinology,
Utrecht, The Netherlands.
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The specific MTHFR and apo E amplified products
were digested using Hinf I (G*AnTC) and Cfo I (GCG*C)
(Roche Diagnostics, Mannheim, Germany), respectively.
Upon digestion, the MTHFR cleaved products were sub-
mitted to electrophoresis on 12% PolyNAT gel (Guest
Elchrom Scientific AG, Basel, Switzerland), while the
apo E cleaved products were analyzed on Spredex EL 400
gel (Guest Elchrom Scientific AG, Basel, Switzerland).
Both gels were stained for 30 min by SYBER Green I day
(Molecular Probes, Leiden, The Netherlands) and destai-
ned overnight by distilled water. Restriction fragments
were visualized under UV transillumination and photo-
graphs were obtained. MTHFR and apo E genotypes
were detected on the basis of restriction fragment length
and unique genotype-dependent band combination.
Plasma Hcy determination
Total plasma Hcy was measured by the enzyme im-
munoassay method (Axis-Shield AS, Oslo, Norway) de-
scribed by Frantzen et al.26. The reference range of Hcy
level was 5–15 (mol/L.
Plasma vitamin B12 and folate determinations
Vitamin B12 and folate were determined by the chem-
iluminescence method using test packages (Bayer Corp.,
NY, USA) for the Bayer ACS:180 Plus autoanalyzer. The
reference values of plasma vitamin B12 and folate were
148–664 pmol/L and 2.5–45.4 nmol/L, respectively.
Plasma lipid determinations
Total cholesterol, HDL cholesterol, and triglycerides
were measured by standard methods using available
tests (Olympus Diagnostica GmbH, Clare, Ireland) for
the Olympus AU 600 autoanalyzer. Total cholesterol and
triglycerides were detected spectrophotometrically, whe-
reas HDL cholesterol was analyzed by a combination of
spectrophotometric and immunoinhibition method. LDL
cholesterol levels were calculated using Friedewald equa-
tion, LDL-cholesterol = (total cholesterol/2.18 – HDL
cholesterol).
Statistical analysis
To analyze Hcy, vitamin B12, folate and lipid differ-
ences, comparisons between groups (classified according
to genotype and two study groups) were carried out with
Mann-Whitney test. The 2-test was used to compare
C677T MTHFR and apo E allele and genotype frequen-
cies as well as distribution in value-dependent (Hcy, vita-
mins and lipids) groups between patients and controls.
The association between homocystein levels (inde-
pendent variable) and CS (dependent variable) was ex-
amined by means of a multiple logistic regression model,
with adjustment for age, sex, and smoking as conven-
tional vascular risk factors. Results were expressed as
odds ratio (OR) together with their 95% confidence inter-
val (CI). Statistical significance was taken as p<0.05.
The statistical programs used were SigmaStat (ver-
sion 2.0, Jandel Corporation, Chicago, IL, USA) for Mann-
Whitney, 2-test and multiple logistic regression analysis,
and a program found on Internet for OR calculation27.
Results
C677T MTHFR and apo E genotype analysis
The frequencies of C677T MTHFR and apo E geno-
types in controls and patients with >70% carotid steno-
sis (CS) are presented in Figure 1.
The frequencies of MTHFR genotypes (CC/TC/TT)
and alleles (C/T) were 45/50/5 and 70/30 in the control
group, and 47/45/8 and 70/30 in the patient group, re-
spectively. C677T MTHFR genotypes were in Hardy-
Weinberg equilibrium (HWE) for CS patients (p=0.972)
and controls (p=0.178). There was no statistically signif-
icant difference between the study groups in the distri-
bution of C677T genotypes (p=0.786) and alleles (p=
0.904).
All three common alleles of apo E were detected,
whereas apo E 2/2 and 4/4 genotypes were not found
among study subjects. The frequencies of apo E geno-
types (3/3, 3/4, 2/3 and 2/4) and alleles (2/3/4) were
80/8/9/3 and 6/88/6 and in the control group, and 50/26/
21/3 and 12/74/14 in the patient group, respectively. Apo


















































Fig. 1. MTHFR (upper panel) and apo E (down panel) genotype
distribution in control subjects (N=60) and carotid stenosis pa-
tients (CS, N=38). *p-value (2-test) for differences among study
group genotype frequencies, **OR (odds ratio) of apo E 3/4 geno-
type was 3.93 (95% CI 1.23–12.61), CI – confidence interval.
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E genotypes were also in HWE for CS patients (p=0.447)
and controls (p=0.920). There was a statistically signifi-
cant difference between CS patients and controls in the
distribution of apo E genotypes (p=0.012) and alleles
(p=0.029). The odds ratio (OR) was 3.93 (95% CI 1.23–
12.61) for apo E 3/4 genotype, 2.93 (95% CI 0.88–9.77) for
apo E 2/3 genotype and 0.78 (95% CI 0.07–8.95) for apo E
2/4 genotype.
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TABLE 1
HOMOCYSTEINE, VITAMIN B12, FOLATE AND LIPIDS IN CONTROL SUBJECTS AND CAROTID STENOSIS PATIENTS WITH DIFFERENT
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Statistical analysis: 2-test for differences among value-dependent (homocysteine, vitamin B12 and folate) groups, and Mann-Whitney
test for differences among genotype-dependent groups.
* For statistical analysis TC and TT MTHFR genotypes were pooled because of the small number of subjects with TT genotype.
** CS – carotid stenosis.
*** Subjects were divided into two groups because only two subjects in control group and one subject in patient group with folate
higher than upper (45.4 nmol/L) level of reference range were found
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C677T MTHFR genotype and levels of Hcy,
vitamin B12, folate and lipids in control subjects
and CS patients
Table 1 shows the distribution of Hcy, vitamin B12,
folate and lipid values (median and range) among control
subjects and CS patients grouped according to MTHFR
genotype.
For statistical analysis, heterozygous, TC, and homo-
zygous, TT genotypes were pooled because of the small
number of subjects with TT genotype (Figure 1; only 5%
of TT genotype in control and 8% in patient group were
found, respectively).
There were no statistically significant differences Hcy
and HDL cholesterol among study groups. Triglycerides,
vitamin B12 and folate were statistically significantly
different in the »all genotypes« group (p0.01, p=0.044
and p=0.036, respectively), and combined (TC/TT) geno-
type group (p=0.003, p=0.030 and p=0.032, respecti-
vely), but not in the group of CC MTHFR genotype. Dif-
ferences in total cholesterol concentrations reached
statistical significance in all three groups (p0.001),
whereas LDL cholesterol did not in the TC/TT group.
Statistical analysis allowed for the results obtained to
summarize. The CS patient group with TC/TT genotype
showed statistically different vitamin B12, folate, total
cholesterol and triglyceride levels in comparison with
control subjects with the same genotype. On comparison,
only total cholesterol and LDL cholesterol reached statis-
tical difference between CS patients with CCMTHFR ge-
notype and controls with the same genotype. Compari-
son of Hcy, vitamin B12, folate and lipids irrespective of
MTHFR and apo E genotype, between patients and con-
trols yielded statistically significant differences for vita-
min B12, folate, total cholesterol, LDL cholesterol and
triglycerides, but not for HDL cholesterol. All these val-
ues showed higher median in patients than in control
subjects, with the exception of Hcy and vitamin B12.
Value-dependent Hcy groups were not statistically
different (Table 1), however, hyperhomocysteinemia (15
(mol/L) was found in 11% of patients and 5% of controls.
Distribution frequencies of vitamin B12 value-dependent
groups showed statistical difference (p=0.021) with 24%
of patients and 5% of controls under the lower normal
value. Only two-folate value-dependent groups were con-
sidered because of the low frequency of patients and con-
trols (two subjects in control and one subject in patient
group) with folate higher than upper (45.5 nmol/L) level
of reference range were found. Distributions of these
groups showed statistical difference (p=0.041).
The findings from the univariate analysis were fur-
ther investigated in a multiple logistic model with in-
clussion of age (in years), sex and smoking habit as a con-
ventional vascular risk factors (Table 2).
The results of multiple logistic analysis showed that
there was no statistical significance of homocystein levels
(OR 2.403, p=0.334) or conventional vascular risk factors
such as smoking habit (OR 0.505, p=0.149), age (OR 1.048,
p=0.087) or sex (OR 2.037, p=0.112) in predicting CS.
Apo E genotype and levels of lipids in control
subjects and CS patients
Table 3 shows the results of lipid analysis in relation
to apo E genotype.
Comparison between the control and CS patient
groups classified according to genotype yielded statistical
differences for some measured lipids (p<0.05). The levels
of total cholesterol, LDL cholesterol and triglycerides in
the apo E 3/3 genotype group yielded statistical differ-
ence. In the group of the apo E 3/4 genotype statistically
significant result was found only for total cholesterol.
Levels of all measured lipids were not different in the
group of apo E 2/3 genotype. Statistical analysis was not
performed in the group of apo E 2/4 genotype group be-
cause only one CS patient had this genotype.
Discussion
In the present study, the association of MTHFR geno-
type with plasma Hcy, vitamin B12, folate and lipids as
well as between apo E genotype and lipids was investi-
gated in the groups of Croatian healthy subjects and pa-
tients with significant (>70%) carotid artery stenosis.
The frequency of C677T MTHFR genotype in study sub-
jects is presented in Figure 1, showing the genotype dis-
tribution to be the same/very similar as previously pub-
lished7,28, although the present study included a smaller
number of subjects. We found no association between CS
and MTHFR genotype. Literature data show controver-
sial results concerning the association of MTHFR geno-
type and carotid artery atherosclerosis, ischemic cere-
brovascular disease (ICVD) and stroke7–10,29.
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TABLE 2
MULTIPLE LOGISTIC REGRESSION ANALYSIS OF RISK FACTORS AND HOMOCYSTEIN LEVELS IN ASSOCIATION WITH CAROTIDE
STENOSIS
$* SE** OR (95%CI)*** p-value
Homocystein 0.877 0.907 2.403 (0.406–14.217) 0.334
Smoking –0.684 0.475 0.505 (0.199–1.279) 0.149
Sex 0.711 0.447 2.037 (0.848–4.896) 0.112
Age 0.046 0.027 1.048 (0.993–1.105) 0.087
*$ – estimated coefficient, **SE – standard error; ***OR – adjusted odds ratio with 95% CI, confidence interval
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Comparison of plasma Hcy level between the patients
and control group matched for sex, age and place of resi-
dence did not show elevated Hcy levels in the CS group
(Table 1). The Hcy median was within the normal range
in both groups. However, hyperhomocysteinemia (15.00
(mol/L) was detected in 5% of controls and in 11% of pa-
tients (Table 1), but did not reach statistical difference.
Epidemiologic data show that hyperhomocysteinemia is
an independent risk factor for atherosclerosis in gene-
ral2,3 and carotid atherosclerosis in particular29,30, how-
ever, there also is a study report that failed to demon-
strate the association between Hcy and CS9.
Vitamin B12 and folate among controls and CS patients
(Table 1) were statistically different in general (group of
»all genotypes«) and in the group of TC/TT MTHFR sub-
jects, however, the median of all values was within the nor-
mal range. Surprisingly, in the group of patients with
TC/TT MTHFR genotype, lower vitamin B12 and higher
folate values were recorded in comparison to the controls.
Additionally, vitamin B12 concentration below the lowest
normal value was found in 24% of patients and only 5% of
controls, while there were 79% of patients and 57% of con-
trols with folate over the lowest normal value (Table 1).
The finding of lower vitamin B12 and higher folate
concentrations in patients as compared with controls is
apparently paradoxical, since neither group of subjects
received folate supplementation. It seems that this find-
ing could be explained by the linked metabolism of folic
acid and vitamin B12, and by the reaction that transfers
methyl group from N5-methyltetrahydrofolate to coba-
lamin30. Namely, in case of cobalamin deficiency, folate is
»trapped« as N5-methyltetrahydrofolate. It is »metaboli-
cally dead« in the absence of vitamin B12 and cannot be
recycled as tetrahydrofolate back into the folate pool.
The collected questionnaires of CS patients showed
that 80% were regular smokers and alcohol consumers,
70% had elevated blood pressure, and 30% had insulin
dependent diabetes mellitus (IDDM). Although a com-
plex disease background of our patient group would pre-
dispose to elevated Hcy levels, they were not recorded in
our study. In contrast to our results, other authors ob-
served positive Hcy association with alcohol and caffeine
intake, smoking, IDDM as well as with hormonal chan-
ges, renal failure, cancer, and some drugs3,31. Additio-
nally, Bo et al. conclude that a high level of alcohol intake
plays a role as an independent risk factor in carotid
atherogenesis. Alcohol intake is independent from other
risk factors such as arterial hypertension, dyslipidemia,
diabetes mellitus, smoking, social status and family his-
tory of cardio-cerebrovascular disease32.
Selhub et al. showed that Hcy exhibited strong in-
verse association with folate and weaker association with
vitamin B12 in extracranial carotid artery stenosis in the
elderly33. Streifler et al. conclude that hyperhomocys-
I. @untar et al.: MTHFR, Apo E, Hcy, Vitamins and Lipids in Carotid Stenosis, Coll. Antropol. 30 (2006) 4: 871–878
876
TABLE 3
LIPID LEVELS IN CONTROL SUBJECTS AND CAROTID STENOSIS PATIENTS WITH DIFFERENT APO E GENOTYPES
Control (N=60);
Genotypes: 3/3 (N=48), 3/4 (N=5),
2/3 (N=5) and 2/4 (N=2);
(median (range)
*CS (N=38);
Genotypes 3/3 (N=19), 3/4 (N=10),







































































*CS – carotid stenosis, **Mann-Whitney test
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teinemia and human platelet antigen (HPA)-1 a/b poly-
morphism are independent risk factors for ischemic
events in patients with significant CS (50%)34.
In contrast, Kostulas et al. report that C677T gene
polymorphism did not exert any major influence on the
risk of developing ICVD or internal carotid artery (ICA)
stenosis, and did not cause Hcy level increase as observed
in ICA stenosis. Also, it was shown that MTHFR geno-
type did not correlate with the levels of either Hcy, folic
acid or vitamin B12, and did not affect Hcy levels, even in
the presence of low blood folate9.
The negative results of multiple logistic regression
analysis of homocystein levels, smoking habit, age and
sex in predicting CS is almost expected because the Hcy
median was within the normal range in both groups.
There is substantial problem of choosing so called control
or healthy group of patients in genetic study. The reason
is because there is no warranty that any of age and sex
match control subject will get illness for a few years, so in
the moment of testing have hyperhomocysteinaemia
showing false positive values in control group.
The statistically significant difference in the distribu-
tion of apo E genotypes (p=0.012) and alleles (p=0.029)
between CS cases and controls indicated the association
between apo E polymorphism and CS. Additionally, OR
was 3.93 (95% CI 1.23–12.61) for apo E 3/4 genotype. The
association of apo E with CS (50%) has been previously
proposed10, and was now confirmed and additionally es-
tablished in severe stenosis (70%) by the present study.
In contrast, Catto et al. find no relationship between apo
E genotype and cerebrovascular disease35. Also, Frikke-
Schmidt et al. showed that apo E polymorphism is a risk
factor for Alzheimer's disease and other dementia inde-
pendent of lipid and lipoprotein levels but does not affect
the risk of ICVD36. Additionally, no association of apo E
polymorphism and carotid atherosclerosis was reported
by others15,17,18, however, there also are reports that con-
firm the existence of such an association16,19,20.
Concerning the results on the association of apo E and
MTHFR genetic polymorphism with blood lipids in pa-
tients with severe CS, we observed some gene effects on
the lipids in the study population. To our knowledge,
there are little or no data on such associations in patients
with severe SC. Our results demonstrated the association
of triglycerides with TC/TT MTHFR (p=0.003) but not
with wild-type MTHFR genotype. HDL cholesterol was
not associated with either wild-type or mutant genotypes,
while total cholesterol was associated with both groups of
genotypes. LDL cholesterol was statistically different only
for CC MTHFR genotype. It has been reported that fast-
ing and postprandial triglyceride-rich lipoproteins (but
not LDLs) are elevated in patients with 50% CS as com-
pared with controls and particularly identify echolucent,
rupture-prone carotid plaques (37). The study of Yatsu et
al. showed that in Caucasians, carotid artery stenosis was
associated with increased plasma total cholesterol and
LDL levels and an atherogenic profile but not with Sac I
polymorphism for apoprotein AI38.
Comparison between the control and CS patient groups
classified according to genotype yielded statistical differ-
ences for some measured lipids as it was shown in Table
3. In the group of the apo E 3/4 genotype statistically sig-
nificant result was found only for total cholesterol, but in
the group of the apo E 3/3 genotype total cholesterol,
LDL cholesterol and triglycerides were significant. Le-
vels of all measured lipids were not different in the group
of apo E 2/3 genotype. Some studies on carotid athero-
sclerosis showed that total cholesterol and LDL choles-
terol were lower in E2 than in E3 and E4 allele carrie-
rs16,19, whereas lower HDL cholesterol and higher LDL
cholesterol were found in the apo E4 group of subjects39.
Similar results, the association of apo E genotypes with
lipids, were obtained for the group of coronary heart dis-
ease in middle-aged women40.
Our study indicated an association of apo E 3/4 geno-
type but not of MTHFR genotype with the risk of CS.
Also, the MTHFR and apo E genotypes were shown to af-
fect blood lipid levels, which was statistically confirmed.
This effect was demonstrated through medians of all val-
ues (the HDL cholesterol values of controls and CS pa-
tients were very close) that were higher in the CS group
compared to control subjects with the same genotype.
Study results showed an association of hyperhomocis-
teinemia with heterozygous/mutant MTHFR genotype in
the CS group, although not statistically confirmed. Also,
the CS group vitamin status was found to be associated
with heterozygous/mutant MTHFR genotype, which was
confirmed statistically, in comparison to controls with
the same genotype. Namely, in the group of patients with
TC/TT MTHFR genotype, lower vitamin B12 and higher
folate values were recorded in comparison to the con-
trols. Our findings are consistent with the concept ac-
cording to which neither genes nor the environment but
their interactions are responsible for the etiopathogene-
sis of complex diseases such as vascular disease. This pre-
liminary study of the association between MTHFR geno-
type and Hcy, vitamin and lipid levels, and between apo E
genotype and lipids revealed that there were associations
that could be clarified and confirmed in further studies.
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POVEZANOST GENOTIPOVA METILENTETRAHIDROFOLAT REDUKTAZE (MTHFR)
I APOLIPOPROTEINA E (APO E) S RAZINOM HOMOCISTEINA, VITAMINA I LIPIDA
U ISPITANIKA SA STENOZOM KAROTIDA
S A @ E T A K
Cilj istra`ivanja bio je ispitivanje povezanosti genotipova metilentetrahidrofolat reduktaze (MTHFR) s razinom ho-
mocisteina (Hcy), folata, vitamina B12 i lipida kao i ispitivanje povezanosti genotipova apolipoproteina E (apo E) s
razinom lipida u zdravoj hrvatskoj kontrolnoj skupini i skupini ispitanika s >70% stenoze karotida (CS). U studiju je
bilo uklju~eno 98 Hrvata, 38 ispitanika s >70% stenozom karotida i 60 kontrolnih uzoraka uskla|enih po dobi i spolu.
Genotipovi MTHFR i apo E odre|eni su metodom lan~ane reakcije polimerazom-polimorfizmom duljine restrikcijskih
fragmenata (PCR-RFLP), Hcy enzimskim imunotestom, vitamini imunokemiluminiscencijom, i lipidi spektrofotome-
trijski. Statisti~ki zna~ajna razlika izme|u kontrola i ispitanika s CS nije na|ena u distribuciji C677T MTHFR genoti-
pova (p=0.786) i alela (p=0.904), dok je u~estalost apo E genotipova (p=0.012) i alela (p=0.029) statisti~ki zna~ajna.
Faktor rizika (eng. odds ratio, OR) za apo E 3/4 genotip iznosio je 3.93 (95% CI 1.23–12.61). Hiperhomocisteinemija
(15 (mol/L) na|ena je u 11% CS ispitanika i 5% kontrola. Ukupni kolesterol, trigliceridi, vitamin B12 i folati statisti~ki
su zna~ajni u skupinama »svi MTHFR genotipovi» (p0.001, p0.01, p=0.044 i p=0.036), i TC/TT genotipovi (p0.001,
p=0.003, p=0.030 i p=0.032). Statisti~ki zna~ajna razlika dobivena je i za ukupni kolesterol, LDL kolesterol i triglice-
ride u skupini s apo E 3/3 genotipom, i za ukupni kolesterol u skupini s apo E 3/4 genotipom. Na|ena je povezanost apo
E 3/4 genotipa, ali ne i MTHFR genotipova s rizikom od CS. Statisti~kom zna~ajno{}u potvr|en je utjecaj MTHFR i apo
E na razinu lipida u krvi. Tako|er je zabilje`ena povezanost hiperhomocisteinemije i ispitanika s CS. Statisti~ki je
potvr|ena povezanost vitaminskog statusa s TC/TT MTHFR genotipom. U skupini ispitanika s TC/TT genotipom na-
|ena je ni`a razina vitamina B12 i vi{a razina folata. Rezultati multiple logisti~ke analize pokazali su da u predskazi-
vanju pojavnosti CS nema statisti~ke zna~ajnosti ni razina Hcy (OR 2.403, p=0.334) niti konvencionalni vaskularni
faktori rizika, kao {to su pu{enje (OR 0.505, p=0.149), godine (OR 1.048, p=0.087) ili spol (OR 2.037, p=0.112).
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